153 related articles for article (PubMed ID: 35998008)
21. The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendations.
Crane G; Lim JCW; Gau CS; Xie J; Chu L
Curr Med Res Opin; 2022 Sep; 38(9):1543-1551. PubMed ID: 35786170
[TBL] [Abstract][Full Text] [Related]
22. Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019.
Inotai A; Németh B
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):379-381. PubMed ID: 31159614
[No Abstract] [Full Text] [Related]
23. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
[TBL] [Abstract][Full Text] [Related]
24. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966
[TBL] [Abstract][Full Text] [Related]
25. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (November 4-6, 2019 - Copenhagen, Denmark).
Kibble A
Drugs Today (Barc); 2019 Nov; 55(11):713-718. PubMed ID: 31840686
[TBL] [Abstract][Full Text] [Related]
26. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12.
Bray B; Ramagopalan SV
J Comp Eff Res; 2023 Jul; 12(7):e230092. PubMed ID: 37345541
[TBL] [Abstract][Full Text] [Related]
27. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomics, Outcomes Research, Health Technology Assessment, Comparative Effectiveness, Patient Centered Outcomes Research in Latin America 2016: brief update.
Augustovski F; Caro J; Ferraz MB; Zárate V
Value Health Reg Issues; 2016 Dec; 11():74-75. PubMed ID: 27986202
[No Abstract] [Full Text] [Related]
29. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
30. Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
Malone DC; Ramsey SD; Patrick DL; Johnson FR; Mullins CD; Roberts MS; Willke RJ; Marshall DA
Value Health; 2020 Apr; 23(4):409-415. PubMed ID: 32327155
[TBL] [Abstract][Full Text] [Related]
31. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
[TBL] [Abstract][Full Text] [Related]
32. Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetReal.
Makady A; Stegenga H; Ciaglia A; Debray TP; Lees M; Happich M; Ryll B; Abrams K; Thwaites R; Garner S; Jonsson P; Goettsch W
J Comp Eff Res; 2017 Sep; 6(6):485-490. PubMed ID: 28857631
[TBL] [Abstract][Full Text] [Related]
33. Access in all areas? A round up of developments in market access and health technology assessment: part 1.
Gilardino R; Treharne C; Mardiguian S; Ramagopalan SV
J Comp Eff Res; 2023 Oct; 12(10):e230129. PubMed ID: 37584405
[TBL] [Abstract][Full Text] [Related]
34. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.
Khorasani E; Davari M; Kebriaeezadeh A; Fatemi F; Akbari Sari A; Varahrami V
Eur J Health Econ; 2022 Dec; 23(9):1577-1590. PubMed ID: 35235078
[TBL] [Abstract][Full Text] [Related]
36. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
[TBL] [Abstract][Full Text] [Related]
37. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
Sievers H; Joos A; Hiligsmann M
Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
[TBL] [Abstract][Full Text] [Related]
38. Value-Based Pricing in Latin America: How Far Away Are We?
Mejía A; Gilardino R; Kristensen FB; Garrison LP;
Value Health Reg Issues; 2018 Dec; 17():219-223. PubMed ID: 30528780
[TBL] [Abstract][Full Text] [Related]
39. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.
Nestler-Parr S; Korchagina D; Toumi M; Pashos CL; Blanchette C; Molsen E; Morel T; Simoens S; Kaló Z; Gatermann R; Redekop W
Value Health; 2018 May; 21(5):493-500. PubMed ID: 29753344
[TBL] [Abstract][Full Text] [Related]
40. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force.
Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ
Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):44-55. PubMed ID: 36215113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
